Celldex (CLDX) Misses Phase 2 Atopic Dermatitis Endpoints, Ends Development
Celldex (CLDX) announced that its Phase 2 trial for barzolvolimab in atopic dermatitis failed to meet primary and key secondary endpoints, leading to the discontinuation of development for this indication. The company continues Phase 3 studies for chronic urticaria with a planned BLA submission in 2027.
How this was made

The 30-second read
Why it matters
The discontinuation removes a potential future catalyst tied to atopic dermatitis and shifts attention to remaining programs, especially chronic urticarias and any path toward a planned BLA there.
Market read
Traders can reassess CLDX pipeline probabilities and near-term catalyst calendar, with the atopic dermatitis leg removed.
What to watch
The article does not quantify how much pipeline value is tied to atopic dermatitis versus chronic urticarias, so market reaction could be muted if the market already discounted that indication.
Background
Celldex is continuing Phase 3 studies in chronic urticarias while ending Phase 2 development in atopic dermatitis for barzolvolimab.
Ticker impact
Celldex reports its Phase 2 barzolvolimab atopic dermatitis trial missed primary and key secondary endpoints and it is discontinuing the indication.
Likely downward pressure as investors reprice the barzolvolimab atopic dermatitis development risk and reduce expectations for future regulatory progress there.
The article states the Phase 2 study missed endpoints and Celldex is ending development in the indication, which is a direct, decision-grade negative catalyst.
Market effects
Adds to biotech sentiment around the difficulty of translating early immunology efficacy into Phase 2 endpoint success.
No clear regional macro linkage; primarily single-name biotech risk repricing.
Limited, mostly affects investors tracking atopic dermatitis and immunology pipeline risk.
Counterpoint
Investors may view the setback as indication-specific, with value preserved by ongoing Phase 3 programs in other diseases.
Key entities
- companyCelldex
Biopharma company discontinuing barzolvolimab development in atopic dermatitis after Phase 2 endpoint misses.
- drug_candidatebarzolvolimab
Celldex investigational therapy whose Phase 2 atopic dermatitis trial missed endpoints.